Vanguard Group Inc Instil Bio, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.63 $10,095 - $15,900	-25,239 Reduced 0.94%	2,672,610 $1.15 Million
Q2 2023 Aug 14, 2023	SELL	$0.51 - $0.67 $146,575 - $192,560	-287,403 Reduced 9.63%	2,697,849 $1.48 Million
Q1 2023 May 15, 2023	SELL	$0.6 - $0.91 $705,853 - $1.07 Million	-1,176,422 Reduced 28.27%	2,985,252 $1.97 Million
Q4 2022 Feb 10, 2023	SELL	$0.48 - $5.33 $452,556 - $5.03 Million	-942,827 Reduced 18.47%	4,161,674 $2.62 Million
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $4.25 Million - $6.74 Million	914,812 Added 21.83%	5,104,501 $24.7 Million
Q2 2022 Aug 12, 2022	BUY	$4.21 - $11.15 $154,928 - $410,320	36,800 Added 0.89%	4,189,689 $19.4 Million
Q1 2022 May 13, 2022	BUY	$8.48 - $18.1 $334,502 - $713,972	39,446 Added 0.96%	4,152,889 $44.6 Million
Q4 2021 Feb 14, 2022	BUY	$15.37 - $22.5 $37.6 Million - $55 Million	2,445,322 Added 146.59%	4,113,443 $70.4 Million
Q3 2021 Nov 12, 2021	BUY	$15.05 - $23.28 $160,643 - $248,490	10,674 Added 0.64%	1,668,121 $29.8 Million
Q2 2021 Aug 13, 2021	BUY	$15.31 - $24.63 $25.4 Million - $40.8 Million	1,657,447 New	1,657,447 $32 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $3.23B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.